EJHaem. 2024 May 8;5(3):638-641. doi: 10.1002/jha2.901. eCollection 2024 Jun.
NO ABSTRACT
PMID:38895077 | PMC:PMC11182393 | DOI:10.1002/jha2.901
Recent Content
- Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
- 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
- Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance
- Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies
- (no title)
- FDA OK’s belantamab mafodotin-blmf for multiple myeloma
- Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value
- (no title)
- (no title)
- (no title)